872254-85-8

Basic information

• Product Name: dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester
• Synonyms: dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester
• CAS NO: 872254-85-8
• Molecular Weight: 288.208
• Mol File: 872254-85-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester(872254-85-8)
• EPA Substance Registry System: dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester(872254-85-8)

Safety Data

• Hazardous Substances Data: 872254-85-8(Hazardous Substances Data)

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 

Downstream Products

• 872259-70-6 3-{4-[1-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-5,5,5-trifluoro-pentyl]-benzoylamino}-propionic acid ethyl ester 
• 872259-69-3 3-{4-[1-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]-benzoylamino}-propionic acid ethyl ester 
• 872259-67-1 4-[1-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester 
• 872259-68-2 4-[1-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]-benzoic acid 
• 872254-84-7 4-bromo-3,5-dimethyl-benzenethiol 

Relevant articles and documents

Active and Unidirectional Acceleration of Biaryl Rotation by a Molecular Motor

Light-driven molecular motors possess immense potential as central driving units for future nanotechnology. Integration into larger molecular setups and transduction of their mechanical motions represents the current frontier of research. Herein we report

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.